Depression Treatment Denied by Insurance: TMS, ECT, and Ketamine Appeals

Major depressive disorder affects over 21 million Americans, and for roughly one-third of patients, standard antidepressants do not provide adequate relief. For these patients, interventional treatments like TMS, ECT, or ketamine infusions are not luxury options — they are medically necessary care. Yet insurance denials for these treatments are among the most common and consequential in mental health coverage. This guide explains how to fight back.

What Gets Denied — and the Real Reasons Why

TMS (Transcranial Magnetic Stimulation): The FDA cleared TMS for major depression in 2008, and the evidence base has grown substantially since. Despite FDA clearance and coverage by Medicare and many commercial plans, TMS Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization denials are extremely common. Typical denial reasons:

• "Adequate trials of antidepressant medications have not been completed" — the insurer disputes whether the patient truly had adequate medication trials
• The plan applies step therapy requiring failure of 3–4 different antidepressants before approving TMS, even when the patient has clear documentation of multiple prior trials
• The specific TMS device or protocol is deemed not covered

ECT (Electroconvulsive Therapy): ECT is one of the most evidence-based treatments in all of psychiatry, with response rates of 60–80% in severe or treatment-resistant depression. It is also commonly covered by Medicare. Commercial insurer denials typically cite ECT as a "last resort" requiring more prior medication failures than the patient has documented, or question the appropriateness of ECT versus alternative interventions.

Ketamine and Esketamine (Spravato): Spravato (esketamine nasal spray) has FDA approval for treatment-resistant depression and is covered by many insurers through prior authorization. IV ketamine infusions remain off-label and are almost universally denied by insurance, despite substantial clinical evidence. The distinction between FDA-approved esketamine and off-label IV ketamine is an important strategy point for appeals.

Medication Denials: Newer antidepressants (Auvelity, Exxua), combination strategies, and high-dose prescribing that exceeds typical formulary limits all face coverage barriers. Step therapy requirements may force patients through inadequate medication trials before accessing effective alternatives.

Proving Medical Necessity for Interventional Treatments

The key to TMS, ECT, and esketamine appeals is documenting a credible history of treatment-resistant depression:

Documenting adequate prior medication trials: "Adequate" means an adequate dose (at or above the minimum therapeutic dose) for an adequate duration (typically 4–6 weeks at therapeutic dose). Specify each medication tried, the dose reached, the duration, and the reason for discontinuation or treatment change. Prior medical records from all treating providers may be needed to reconstruct this history.

APA Practice Guidelines: The American Psychiatric Association's Practice Guideline for the Treatment of Patients With Major Depressive Disorder endorses TMS and ECT as indicated treatments for treatment-resistant depression. Cite these guidelines directly in your appeal.

HEDIS and quality measures: Note that HEDIS measures and accreditation standards support appropriate use of these treatments, reinforcing that denials are clinically inconsistent with standard of care.

Functional impairment documentation: PHQ-9 scores, GAF/WHODAS scores, documentation of inability to work, maintain relationships, or perform activities of daily living strengthen the argument that treatment-resistant depression is a serious, debilitating condition warranting advanced intervention.

Mental Health Parity Act (MHPAEA) Explained" class="auto-link">mhpaea-in-depression-appeals">MHPAEA in Depression Appeals

Under MHPAEA, the step-therapy requirements applied to depression medications and interventional depression treatments must be comparable to those applied to analogous medical/surgical treatments. If your insurer requires failure of 4 antidepressants before approving TMS but does not require equivalent prior failure trials before approving comparable medical interventions, that may constitute a parity violation.

Request your plan's NQTL comparative analysis in writing. This document must show how the plan applies its criteria for TMS and ECT compared to comparable medical procedures (e.g., neurostimulation for chronic pain, cardiac interventions with similar evidence bases).

Building Your Appeal Step by Step

1. Compile complete medication history — including doses, durations, prescribers, and discontinuation reasons
2. Have your psychiatrist write a detailed medical necessity letter citing the patient's specific treatment history, current severity, APA guidelines, and directly responding to the insurer's stated denial criteria
3. Request peer-to-peer review — psychiatrist to insurer's medical director — before the formal appeal deadline
4. File a comprehensive internal appeal including medication records, psychiatric evaluations, PHQ-9 scores, and clinical guideline citations
5. Request External Independent Review: Complete Guide" class="auto-link">external review if internal appeal fails — external reviewers with psychiatry expertise regularly overturn TMS and ECT denials
6. For Spravato (esketamine): Follow the REMS program requirements carefully; documentation of FDA-required prior treatment failures must be complete and in the medical record

What About Medicare Patients?

Medicare Part B covers TMS for major depressive disorder and covers ECT. If you are a Medicare patient and your claim is being denied, the appeals process involves specific CMS rules — including Redetermination, Reconsideration, ALJ hearing, and Medicare Appeals Council — with different timelines than commercial insurance appeals.

Fight Back With ClaimBack

Treatment-resistant depression is serious, but your appeal is winnable. ClaimBack helps you build the clinical and legal case that insurers need to see before they approve coverage.

Start your depression treatment insurance appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter That Gets Results
• What Is Medical Necessity — and How to Prove It to Your Insurer
• Internal vs. External Insurance Appeals: Which Path Is Right for You?